-
Je něco špatně v tomto záznamu ?
Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study
A. Martan, J. Masata, J. Krhut, R. Zachoval, T. Hanus, K. Svabik,
Jazyk angličtina Země Irsko
Typ dokumentu klinická studie, časopisecké články, multicentrická studie
- MeSH
- acetanilidy terapeutické užití MeSH
- adherence k farmakoterapii statistika a číselné údaje MeSH
- agonisté beta-3-adrenergních receptorů terapeutické užití MeSH
- dospělí MeSH
- hyperaktivní močový měchýř farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- thiazoly terapeutické užití MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinická studie MeSH
- multicentrická studie MeSH
OBJECTIVE: The objective of this project was to evaluate treatment persistence in patients being treated for overactive bladder syndrome (OAB) with mirabegron, employing clinical follow-up in a prospective, multicenter study. STUDY DESIGN: This is an analysis of patients who started treatment with mirabegron between May and September 2014 and were evaluated 1year after treatment commenced. During this evaluation we determined how many patients stopped treatment and established their reasons for discontinuation. RESULTS: 206 patients being treated for OAB with mirabegron were evaluated a year after starting treatment. It emerged that 60 patients (29.1%) had discontinued the treatment, citing the following reasons: 24/60 insufficient treatment efficacy, 26/60 other reasons, while 10 members of the group discontinued treatment because of side effects. 75 out of 206 patients were ≤60 years old and 28% terminated the study prematurely: 131 out of 206 were >60years old and 29.2% terminated the study prematurely. In the group of patients without previous OAB treatment 35.7% discontinued treatment with mirabegron, while 28.1% of patients with previous anticholinergic treatment discontinued treatment. CONCLUSION: In our clinical prospective multicenter study, persistence in treatment with mirabegron reached a figure of 71%.
Department of Urology Thomayer Hospital Prague Czechia
Department of Urology University Hospital in Ostrava Czechia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010859
- 003
- CZ-PrNML
- 005
- 20180420092956.0
- 007
- ta
- 008
- 180404s2017 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejogrb.2016.12.030 $2 doi
- 035 __
- $a (PubMed)28073038
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Martan, Alois $u Department of Obstetrics and Gynecology, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czechia. Electronic address: martan@vfn.cz.
- 245 10
- $a Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study / $c A. Martan, J. Masata, J. Krhut, R. Zachoval, T. Hanus, K. Svabik,
- 520 9_
- $a OBJECTIVE: The objective of this project was to evaluate treatment persistence in patients being treated for overactive bladder syndrome (OAB) with mirabegron, employing clinical follow-up in a prospective, multicenter study. STUDY DESIGN: This is an analysis of patients who started treatment with mirabegron between May and September 2014 and were evaluated 1year after treatment commenced. During this evaluation we determined how many patients stopped treatment and established their reasons for discontinuation. RESULTS: 206 patients being treated for OAB with mirabegron were evaluated a year after starting treatment. It emerged that 60 patients (29.1%) had discontinued the treatment, citing the following reasons: 24/60 insufficient treatment efficacy, 26/60 other reasons, while 10 members of the group discontinued treatment because of side effects. 75 out of 206 patients were ≤60 years old and 28% terminated the study prematurely: 131 out of 206 were >60years old and 29.2% terminated the study prematurely. In the group of patients without previous OAB treatment 35.7% discontinued treatment with mirabegron, while 28.1% of patients with previous anticholinergic treatment discontinued treatment. CONCLUSION: In our clinical prospective multicenter study, persistence in treatment with mirabegron reached a figure of 71%.
- 650 _2
- $a acetanilidy $x terapeutické užití $7 D000083
- 650 _2
- $a agonisté beta-3-adrenergních receptorů $x terapeutické užití $7 D058667
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a adherence k farmakoterapii $x statistika a číselné údaje $7 D055118
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a thiazoly $x terapeutické užití $7 D013844
- 650 _2
- $a hyperaktivní močový měchýř $x farmakoterapie $7 D053201
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a klinická studie $7 D000068397
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Masata, Jaromir $u Department of Obstetrics and Gynecology, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czechia. Electronic address: masata@volny.cz.
- 700 1_
- $a Krhut, Jan $u Department of Urology, University Hospital in Ostrava, Czechia. Electronic address: jan.krhut@fno.cz.
- 700 1_
- $a Zachoval, Roman $u Department of Urology, Thomayer Hospital in Prague, Czechia. Electronic address: roman.zachoval@ftn.cz.
- 700 1_
- $a Hanus, Tomas $u Department of Urology, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czechia. Electronic address: tomas.hanus@lf1.cuni.cz.
- 700 1_
- $a Svabik, Kamil $u Department of Obstetrics and Gynecology, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czechia. Electronic address: kamil@svabik.cz.
- 773 0_
- $w MED00001632 $t European journal of obstetrics, gynecology, and reproductive biology $x 1872-7654 $g Roč. 210, č. - (2017), s. 247-250
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28073038 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180420093058 $b ABA008
- 999 __
- $a ok $b bmc $g 1288344 $s 1007671
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 210 $c - $d 247-250 $e 20161223 $i 1872-7654 $m European journal of obstetrics, gynecology and reproductive biology $n Eur J Obstet Gynecol Reprod Biol $x MED00001632
- LZP __
- $a Pubmed-20180404
